MicroRNAs As Therapeutics for Future Drug Delivery Systems in Treatment of Lung Diseases

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2016 Nov 17

PMID 27848224

Citations 16

Authors

Kamal Dua

Nicole G Hansbro

Paul S Foster

Philip M Hansbro

Affiliations

Soon will be listed here.

Abstract

The rapid advancement in the area of microRNAs (miRNAs) from discovery to their translation into therapeutic moieties reflects their significance as important regulators in the management of disease pathology. The miRNAs can potentially be a new class of drugs in the near future for the treatment of various lung diseases, but it lacks the current knowledge how these identified therapeutic moieties can be designed into an effective, patient complaint and targeted drug delivery system. miRNAs have characteristic features like small size and low molecular weight which makes them easily translated into an effective drug delivery system. In this review, we have summarised the concept of miRNAs and different approaches which can be employed to deliver miRNAs effectively and safely to the target cells including the challenges associated with their development in particular emphasis on pulmonary diseases. Such approaches will be of interest for both the biological and formulation scientists to understand and explore the new vistas in the area of miRNA delivery for pulmonary inflammatory diseases.

Citing Articles

MicroRNAs as promising drug delivery target to ameliorate chronic obstructive pulmonary disease using nano-carriers: a comprehensive review.

Khanna V, Singh K Mol Cell Biochem. 2024; 480(3):1431-1448.

PMID: 39254870 DOI: 10.1007/s11010-024-05110-0.

Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.

Dume B, Licarete E, Banciu M Mol Ther Nucleic Acids. 2024; 35(3):102256.

PMID: 39045515 PMC: 11264197. DOI: 10.1016/j.omtn.2024.102256.

Revisiting Skeletal Muscle Dysfunction and Exercise in Chronic Obstructive Pulmonary Disease: Emerging Significance of Myokines.

Han L, Li P, He Q, Yang C, Jiang M, Wang Y Aging Dis. 2024; 15(6):2453-2469.

PMID: 38270119 PMC: 11567253. DOI: 10.14336/AD.2023.1125.

Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions.

Sahu P, Donovan C, Paudel K, Pickles S, Chimankar V, Kim R Front Oncol. 2023; 13:1260411.

PMID: 37817767 PMC: 10560855. DOI: 10.3389/fonc.2023.1260411.

Nrf2 regulates downstream genes by targeting miR-29b in severe asthma and the role of grape seed proanthocyanidin extract in a murine model of steroid-insensitive asthma.

Qian Y, Sun Y, Chen Y, Mao Z, Shi Y, Wu D Pharm Biol. 2022; 60(1):347-358.

PMID: 35171066 PMC: 8856085. DOI: 10.1080/13880209.2022.2032205.

References

Ibrahim A, Weirauch U, Thomas M, Grunweller A, Hartmann R, Aigner A . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71(15):5214-24. DOI: 10.1158/0008-5472.CAN-10-4645. View

Tivnan A, Orr W, Gubala V, Nooney R, Williams D, McDonagh C . Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One. 2012; 7(5):e38129. PMC: 3360657. DOI: 10.1371/journal.pone.0038129. View

Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K . Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010; 17(6):398-408. DOI: 10.1038/cgt.2009.88. View

Kumar A, Bicer E, Morgan A, Pfeffer P, Monopoli M, Dawson K . Enrichment of immunoregulatory proteins in the biomolecular corona of nanoparticles within human respiratory tract lining fluid. Nanomedicine. 2016; 12(4):1033-1043. DOI: 10.1016/j.nano.2015.12.369. View

Sharma A, Kumar M, Ahmad T, Mabalirajan U, Aich J, Agrawal A . Antagonism of mmu-mir-106a attenuates asthma features in allergic murine model. J Appl Physiol (1985). 2012; 113(3):459-64. DOI: 10.1152/japplphysiol.00001.2012. View

Kumar A, Forbes B, Mudway I, Bicer E, Dailey L . What are the biological and therapeutic implications of biomolecule corona formation on the surface of inhaled nanomedicines?. Nanomedicine (Lond). 2015; 10(3):343-5. DOI: 10.2217/nnm.15.2. View

Zwiers A, Kraal L, van de Pouw Kraan T, Wurdinger T, Bouma G, Kraal G . Cutting edge: a variant of the IL-23R gene associated with inflammatory bowel disease induces loss of microRNA regulation and enhanced protein production. J Immunol. 2012; 188(4):1573-7. DOI: 10.4049/jimmunol.1101494. View

van Dommelen S, Vader P, Lakhal S, Kooijmans S, van Solinge W, Wood M . Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release. 2011; 161(2):635-44. DOI: 10.1016/j.jconrel.2011.11.021. View

Hutvagner G, McLachlan J, Pasquinelli A, Balint E, Tuschl T, Zamore P . A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001; 293(5531):834-8. DOI: 10.1126/science.1062961. View

10.

Cullen B . Transcription and processing of human microRNA precursors. Mol Cell. 2004; 16(6):861-5. DOI: 10.1016/j.molcel.2004.12.002. View

11.

Zhang Y, Wang Z, Gemeinhart R . Progress in microRNA delivery. J Control Release. 2013; 172(3):962-74. PMC: 3891846. DOI: 10.1016/j.jconrel.2013.09.015. View

12.

Chen C, Li L, Lodish H, Bartel D . MicroRNAs modulate hematopoietic lineage differentiation. Science. 2003; 303(5654):83-6. DOI: 10.1126/science.1091903. View

13.

Xie T, Liang J, Liu N, Wang Q, Li Y, Noble P . MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I. J Immunol. 2012; 188(5):2437-44. PMC: 3288289. DOI: 10.4049/jimmunol.1101070. View

14.

M Greene C, Gaughan K . microRNAs in asthma: potential therapeutic targets. Curr Opin Pulm Med. 2012; 19(1):66-72. DOI: 10.1097/MCP.0b013e32835a5bc8. View

15.

Wiggins J, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D . Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010; 70(14):5923-30. PMC: 2913706. DOI: 10.1158/0008-5472.CAN-10-0655. View

16.

Yamamoto M, Singh A, Ruan J, Gauvreau G, OByrne P, Carlsten C . Decreased miR-192 expression in peripheral blood of asthmatic individuals undergoing an allergen inhalation challenge. BMC Genomics. 2012; 13:655. PMC: 3598672. DOI: 10.1186/1471-2164-13-655. View

17.

Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J . The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415-9. DOI: 10.1038/nature01957. View

18.

Oglesby I, Bray I, Chotirmall S, Stallings R, ONeill S, McElvaney N . miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol. 2010; 184(4):1702-9. DOI: 10.4049/jimmunol.0902669. View

19.

Grishok A, Pasquinelli A, Conte D, Li N, Parrish S, Ha I . Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell. 2001; 106(1):23-34. DOI: 10.1016/s0092-8674(01)00431-7. View

20.

Witwer K, Sisk J, Gama L, Clements J . MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol. 2010; 184(5):2369-76. PMC: 3076721. DOI: 10.4049/jimmunol.0902712. View